文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

单中心遗传性弥漫性胃癌的全胃切除术:41例患者的术后结果

Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients.

作者信息

Strong Vivian E, Gholami Sepideh, Shah Manish A, Tang Laura H, Janjigian Yelena Y, Schattner Mark, Selby Luke V, Yoon Sam S, Salo-Mullen Erin, Stadler Zsofia K, Kelsen David, Brennan Murray F, Coit Daniel G

机构信息

*Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY †Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY ‡Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY §Department of Gastroenterology, Memorial Sloan Kettering Cancer Center, New York, NY ¶Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, NY.

出版信息

Ann Surg. 2017 Dec;266(6):1006-1012. doi: 10.1097/SLA.0000000000002030.


DOI:10.1097/SLA.0000000000002030
PMID:27759617
Abstract

OBJECTIVE: The aim of this study was to describe postoperative outcomes of total gastrectomy at our institution for patients with hereditary diffuse gastric cancer (HDGC). BACKGROUND: HDGC, which is mainly caused by germline mutations in the E-cadherin gene (CDH1), renders a lifetime risk of gastric cancer of up to 70%, prompting a recommendation for prophylactic total gastrectomy. METHODS: A prospective gastric cancer database identified 41 patients with CDH1 mutation who underwent total gastrectomy during 2005 to 2015. Perioperative, histopathologic, and long-term data were collected. RESULTS: Of the 41 patients undergoing total gastrectomy, median age was 47 years (range 20 to 71). There were 14 men and 27 women, with 25 open operations and 16 minimally invasive operations. Median length of stay was 7 days (range 4 to 50). In total, 11 patients (27%) experienced a complication requiring intervention, and there was 1 peri-operative mortality (2.5%). Thirty-five patients (85%) demonstrated 1 or more foci of intramucosal signet ring cell gastric cancer in the examined specimen. At 16 months median follow-up, the median weight loss was 4.7 kg (15% of preoperative weight). By 6 to 12 months postoperatively, weight patterns stabilized. Overall outcome was reported to be "as expected" by 40% of patients and "better than expected" by 45%. Patient-reported outcomes were similar to those of other patients undergoing total gastrectomy. CONCLUSION: Total gastrectomy should be considered for all CDH1 mutation carriers because of the high risk of invasive diffuse-type gastric cancer and lack of reliable surveillance options. Although most patients have durable weight loss after total gastrectomy, weights stabilize at about 6 to 12 months postoperatively, and patients report outcomes as being good to better than their preoperative expectations. No patients have developed gastric cancer recurrence after resections.

摘要

目的:本研究旨在描述我院对遗传性弥漫性胃癌(HDGC)患者行全胃切除术后的结局。 背景:HDGC主要由E-钙黏蛋白基因(CDH1)的种系突变引起,其患胃癌的终生风险高达70%,因此建议行预防性全胃切除术。 方法:通过前瞻性胃癌数据库确定了2005年至2015年间41例因CDH1突变而行全胃切除术的患者。收集围手术期、组织病理学和长期数据。 结果:41例行全胃切除术的患者中,中位年龄为47岁(范围20至71岁)。男性14例,女性27例,其中25例为开放手术,16例为微创手术。中位住院时间为7天(范围4至50天)。共有11例患者(27%)出现需要干预的并发症,围手术期死亡1例(2.5%)。35例患者(85%)的检查标本中显示有1个或更多黏膜内印戒细胞型胃癌病灶。中位随访16个月时,中位体重减轻4.7kg(占术前体重的15%)。术后6至12个月时,体重模式趋于稳定。40%的患者报告总体结局“与预期相符”,45%的患者报告“好于预期”。患者报告的结局与其他行全胃切除术的患者相似。 结论:由于侵袭性弥漫型胃癌风险高且缺乏可靠的监测方法,所有CDH1突变携带者均应考虑行全胃切除术。虽然大多数患者在全胃切除术后体重持续减轻,但术后约6至12个月体重趋于稳定,且患者报告结局良好至好于术前预期。切除术后无患者发生胃癌复发。

相似文献

[1]
Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients.

Ann Surg. 2017-12

[2]
Laparoscopic Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer in Mutation Carriers.

J Laparoendosc Adv Surg Tech A. 2021-7

[3]
[From gene to disease; E-cadherin and hereditary diffuse gastric cancer].

Ned Tijdschr Geneeskd. 2003-12-13

[4]
Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies.

JAMA Surg. 2020-11-1

[5]
Therapeutic and prophylactic gastrectomy in a family with hereditary diffuse gastric cancer secondary to a CDH1 mutation: a case series.

World J Surg Oncol. 2018-7-14

[6]
Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications.

Am J Surg Pathol. 2008-6

[7]
Prophylactic Laparoscopic Total Gastrectomy with Jejunal Pouch Reconstruction in Patients Carrying a CDH1 Germline Mutation.

J Gastrointest Surg. 2015-12

[8]
CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer.

Ann Surg. 2007-6

[9]
A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer.

Ann Surg Oncol. 2011-3-18

[10]
Germline mutation of the E-cadherin gene in three sibling cases with advanced gastric cancer: clinical consequences for the other family members.

Eur J Gastroenterol Hepatol. 2010-3

引用本文的文献

[1]
Lessons learned from 150 total gastrectomies for prevention of cancer.

J Gastrointest Surg. 2025-1

[2]
Chinese national clinical practice guidelines on the prevention, diagnosis, and treatment of early gastric cancer.

Chin Med J (Engl). 2024-4-20

[3]
Jeff Norton and the Definition of 'Un'.

Ann Surg Oncol. 2024-6

[4]
A Systematic Review on Clinical and Health-Related Quality of Life Outcomes following Total Gastrectomy in Patients with Hereditary Diffuse Gastric Cancer.

Cancers (Basel). 2024-1-23

[5]
Pioneering use of genetic analysis for to identify candidates for prophylactic total gastrectomy to prevent hereditary diffuse gastric cancer.

eGastroenterology. 2023-9

[6]
Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy.

J Clin Oncol. 2024-2-1

[7]
Case Series of 11 Families (47 Carriers) Including Incidental Findings, Signet Ring Cell Colon Cancer and Review of the Literature.

Genes (Basel). 2023-8-25

[8]
Laparoscopic prophylactic total gastrectomy with limited lymphadenectomy for CDH1 gene carriers.

Surg Endosc. 2023-12

[9]
Unique Genomic Alterations and Microbial Profiles Identified in Patients With Gastric Cancer of African, European, and Asian Ancestry: A Novel Path for Precision Oncology.

Ann Surg. 2023-10-1

[10]
Risk-reducing surgery for individuals with cancer-predisposing germline pathogenic variants and no personal cancer history: a review of current UK guidelines.

Br J Cancer. 2023-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索